ANI Pharma (ANIP) Reports Q4 EPS of 84c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance
March 2, 2017 8:30 AM ESTBAUDETTE, Minn., March 2, 2017 /PRNewswire/ --
For the full year ended December 31, 2016:
Record net revenues of $128.6 million, an increase of 69% versus the prior year GAAP net income of $3.9 million, including $6.7 million non-cash impairment charge for a non-core asset Diluted GAAP earnings per share of $0.34, including impact of non-cash impairment charge of $0.36, net of tax Adjusted non-GAAP EBITDA of $61.1 million Adjusted non-GAAP net income per diluted share of $3.78 (previous methodology)For the fourth quarter 2016:
Net... More